Combination immunotherapy targets cancer resistance

November 22, 2017 by Ziba Kashef, Yale University
Image shows infiltration of transplanted human cancer cells (yellow/orange) by two myeloid cell subsets (red and green) in a mouse model treated with combination immunotherapy. Credit: Yale University

Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this problem by targeting a wider range of immune cells linked to tumor growth.

Existing cancer immunotherapies act on only a fraction of immune cells implicated in the disease. In this study, the research team developed an antibody, KWAR23, to block a different set of known as . Many of these cells infiltrate tumors, triggering , inflammation, and resistance to treatment.

In both cell culture and in mouse models with human cell membrane proteins, the research team found that the antibody blocked a protein that would otherwise limit the tumor-killing ability of myeloid cells. In combination with an approved cancer immunotherapy drug, the antibody significantly limited tumor cell growth.  

The finding demonstrates a promising combination therapeutic approach to more effectively fight tumors, the researchers said. It will also lead to further research to examine whether the antibody is also effective in reducing more advanced and metastatic cancers.

The study is published in PNAS.

Explore further: Researchers uncover novel mechanism by which tumors evade cancer immunotherapies

More information: Nan Guo Ring et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity, Proceedings of the National Academy of Sciences (2017). DOI: 10.1073/pnas.1710877114

Related Stories

Researchers uncover novel mechanism by which tumors evade cancer immunotherapies

November 10, 2017
A Ludwig Cancer Research study led by Benoit Van den Eynde, Director of Ludwig Brussels, has identified a novel mechanism by which tumors of the aggressive skin cancer melanoma can resist cancer immunotherapy. Their paper, ...

Preclinical study finds antitumor effects of bispecific antibody

October 5, 2017
Chugai Pharmaceutical announced today that the preclinical study findings on its original bispecific antibody ERY974, a molecule that binds Glypican-3 and CD3 simultaneously, and that is currently under development as a Phase ...

New chimeric antibody that suppresses malignant cancers in dogs

August 25, 2017
Similar to humans, dogs live longer than before and an increasing number of them die from cancer. As seen in humans, dogs have malignant cancers that cannot be treated by existing therapies such as surgery, radiotherapy and ...

Cell surface protein may offer big target in treating high-risk childhood cancers

September 11, 2017
Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy—harnessing the immune system in medical treatments. In cell cultures and animal models, ...

Tumor-infiltrating B lymphocytes promote melanoma progression and resistance to therapy

September 19, 2017
In a multi-institutional collaborative study, scientists at The Wistar Institute and the Medical University of Vienna, Austria, have identified the role of tumor-infiltrating or tumor-associated B-cells ("TABs") in melanoma ...

Targeting blood vessels to improve cancer immunotherapy

April 12, 2017
EPFL scientists have improved the efficacy of cancer immunotherapy by blocking two proteins that regulate the growth of tumor blood vessels.

Recommended for you

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

New way to target advanced breast cancers

September 20, 2018
A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.